Implementation of Pharmacogenetic Testing in Hospital Wards (FAGLIS)

Hospital Pharmacy Enterprise, South Eastern Norway

Status

Completed

Conditions

Admitted Multimorbid Patients

Treatments

Other: Medication review

Genetic: Pharmacogenetic test

Study type

Interventional

Funder types

Other

Identifiers

NCT04573491

IMP-CYP SA HF 2020-001

Details and patient eligibility

About

The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.

Full description

Earlier studies have shown that pharmacogenetic testing may contribute to optimizing the efficacy of medication treatment and to reduce the risk of adverse effects. Inclusion of pharmacogenetic testing as part of medication reviews reveals more serious drug related problems and leads to more changes in medication treatment than medication review alone.

The use of pharmacogenetic testing as part of medication reviews has not earlier been systematically investigated in hospital patients in Norway. There is little documentation of what is needed to implement the use of pharmacogenetic testing in a hospital ward.

The investigators are conducting a descriptive study in two internal medicine wards at Akershus University Hospital. 50 patients using minimum 5 regular drugs including at least one relevant for pharmacogenetic testing will be enrolled in the study.

Enrollment

46 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

at least 2 long-term conditions
at least 5 regular drugs of which at least one relevant for pharmacogenetic testing
at least 2 years life expectancy
able to communicate in Norwegian
able to give informed consent
summary care record

Exclusion criteria